The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Critical Challenges in PD: Alpha-synuclein Neuroimaging, 2008Generation of Alpha-Synuclein Conformation Specific Aptamers for In Vivo Bioimaging of Alpha-Synuclein Pathology
Objective/Rationale:
Alpha-synuclein is an abundant brain protein, whose misfolding has been associated to the development of Parkinson’s disease. Visualization of the different misfolded forms of... -
Alpha-Synuclein Imaging, 2008In Vivo SPECT Imaging of Alpha-Synuclein Aggregation with Morphology Specific Antibody Based Ligands
Objective/Rationale:
The protein alpha-synuclein is a major constituent of the Lewy Body aggregates that are a hallmark feature of Parkinson’s disease and has been strongly correlated with the disease... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Image-Guided Convective Delivery of AAV Vectors
Objective/Rationale:
Gene transfer technology holds promise to permanently alter the natural course of PD. However, in order for this technology to work there is a critical need for safe, reproducible... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Convection Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Human Parkinson's disease
Objective/Rationale:
Infusion of neuroactive drugs into targeted nuclei of the basal ganglia involved in Parkinson’s disease should provide critical insight into the role of neurotransmitters in these... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Real-time Monitoring of Targeting, Delivery and Spread of Therapeutic Agents in the Brain
Objective/Rationale:
Current drug therapy for Parkinson’s disease has limited long term effectiveness. To improve therapy in the future, delivery of therapeutic agents to the brain will be an... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Deep brain imaging to determine movement of compounds relevant to Parkinson's disease
Objective/Rationale:
Clinical trials with a number of agents suggest that the ability of compounds to move through the interstitial spaces of the brain is a critical factor for their effectiveness...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.